124276-55-7

Usage

Uses

Used in Pharmaceutical Research and Development:
Cyclopropanecarbonitrile, 1-(3-fluorophenyl)(9CI) is used as a reagent in organic synthesis for the development of new drug molecules. Its unique chemical properties and strong bonding capabilities make it a valuable component in the design and synthesis of innovative pharmaceutical compounds.
Used in Organic Synthesis:
In the field of organic synthesis, Cyclopropanecarbonitrile, 1-(3-fluorophenyl)(9CI) is utilized as a key intermediate for the creation of various chemical compounds. Its ability to form strong bonds and its unique structure contribute to the synthesis of a wide range of organic molecules.

Upstream product

• 501-00-8 3-fluorophenylacetonitrile 
• 106-93-4 ethylene dibromide 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 886365-90-8 1-(3-fluorophenyl)cyclopropyl methylamine 
• 1039454-25-5 C₂₂H₂₀FN₃O₅ 
• 248588-33-2 1-(3-fluorophenyl)cyclopropane-1-carboxylic acid 

Relevant academic research and scientific papers

Preparation method of arylcyclopropane compound

The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.